title: Cardiotoxicity of molecularly targeted agents.
abstract: Cardiac toxicity of molecularly targeted cancer agents is increasingly recognized as a significant side effect of chemotherapy. These new potent therapies may not only affect the survival of cancer cells, but have the potential to adversely impact normal cardiac and vascular function. Unraveling the mechanisms by which these therapies affect the heart and vasculature is crucial for improving drug design and finding alternative therapies to protect patients predisposed to cardiovascular disease. In this review, we summarize the classification and side effects of currently approved molecularly targeted chemotherapeutics.
authors: Department of Internal Medicine-Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT 06520-8017, USA.
authors: Nadia
authors: N
authors: Hedhli
authors: Kerry S
authors: KS
authors: Russell
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000145:classification; D054715:Cardiotoxins / Q000009:adverse effects* / Q000145:classification; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D058990:Molecular Targeted Therapy / Q000009:adverse effects* / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D054715:Cardiotoxins